Lidokain Aguettant (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium ions that initiates an action potential. This reversible blockade stops nerve impulse transmission, resulting in localized numbness without affecting consciousness.

The appropriate dose of Lidokain Aguettant is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical context. Healthcare professionals calculate the dose to stay within recommended maximum limits and to achieve effective anesthesia.

Safety of lidocaine during pregnancy or lactation should be evaluated by the treating physician. While lidocaine is classified as a Category B drug in many regions, the prescriber must weigh potential benefits against any theoretical risks to the fetus or infant before administration.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for many outpatient procedures. Compared with agents such as bupivacaine, lidocaine has a shorter half‑life and lower cardiotoxic potential, but may require repeat dosing for longer surgeries.

Lidokain Aguettant should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations to maintain sterility and potency.

The product is supplied as a sterile solution for infiltration into the target tissue or for intravenous infusion. Administration is performed by qualified healthcare professionals using aseptic technique, with dosage adjusted to the procedure and patient characteristics.

Serious risks include systemic toxicity, which can manifest as seizures, cardiac arrhythmias, or severe hypotension, and rare allergic reactions such as anaphylaxis. Prompt recognition and supportive management are essential if systemic signs develop.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled epilepsy, or significant hepatic impairment should avoid using Lidokain Aguettant unless a specialist determines that benefits outweigh risks.